Clinical Trial Update: Switching Undetectables to Selzentry [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating switching patients with undetectable HIV to Selzentry (maraviroc) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immune Deficiency Syndrome
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Selzentry (Maraviroc)

Snippet

Sponsor: St. Hope Foundation | Conditions: Human Immunodeficiency Virus, AIDS | Phase 4 | Status: COMPLETED